

## LETTER

## Reciprocal Modulation of Terminal Sialylation and Bisecting *N*-Glycans: A New Axis of Cancer-Cell Glycome Regulation?

Lu *et al.* (1) have investigated the influence of cellular sialylation on the GnT-III-mediated regulation of cancer cell metastatic potential. The authors demonstrated that GnT-III (GlcNAc-bisecting glycosyltransferase) overexpression results in a significant reduction of  $\alpha$ 2,3-sialylation, with no major alteration of  $\alpha$ 2,6-sialylation (1). Interestingly, a reciprocal correlation between terminal  $\alpha$ 2,3-sialylation and bisected *N*-glycans has also been recently reported (2). Glycomic analysis of cancer cells overexpressing the  $\alpha$ 2,3-sialyltransferase ST3GAL4 showed that increased terminal  $\alpha$ 2,3-sialylation is accompanied by a substantial loss of bisected *N*-glycans (2).

This coordinated regulation of  $\alpha$ 2,3-sialylation by bisecting *N*-glycans and vice versa adds a new level of complexity to the regulation of the cancer cell glycome and raises new questions about the molecular mechanisms underlying these glycosylation shifts. Noteworthy, the down-regulation of bisected *N*-glycans and  $\alpha$ 2,3-sialylation by ST3GAL4 and GnT-III, respectively, do not stem from alterations at the glycosyltransferase transcript levels (1, 2). The supramolecular organization of the Golgi glycosylation pathways is plastic and can be altered in cancer cells (3); thus, we can hypothesize that altered localization of the overexpressed glycosyltransferases could functionally impact the sequential glycan biosynthetic pathways and therefore interfere with bisecting *N*-glycans and terminal sialylation.

Increased  $\alpha$ 2,3-sialylation is associated with malignancy and patients' poorer prognosis, whereas bisected *N*-glycans suppress metastization (4). Moreover, *N*-glycan branching and sialylation patterns determine galectin lattice dynamics with critical impact on tumor cell signaling and definition of aggressiveness features (5). Therefore, deciphering the mechanisms underlying reciprocal regulation of terminal sialylation and bisecting *N*-glycans is fundamental for our understanding of tumor cell biology.

 Ana Magalhães<sup>†§1</sup>, Stefan Mereiter<sup>†§¶</sup>, and Celso Reis<sup>†§¶||1</sup>

<sup>†</sup>*i3S-Instituto de Investigação e Inovação em Saúde*, <sup>¶</sup>*Institute of Biomedical Sciences of Abel Salazar-ICBAS*, and <sup>||</sup>*Medical Faculty, University of Porto, Porto, Portugal* and <sup>§</sup>*Institute of Molecular Pathology and Immunology, University of Porto-IPATIMUP, Porto, Portugal*

- 1 Lu, J., Isaji, T., Im, S., Fukuda, T., Kameyama, A., and Gu, J. (2016) Expression of *N*-acetylglucosaminyltransferase III suppresses  $\alpha$ 2,3-sialylation and its distinctive functions in cell migration are attributed to  $\alpha$ 2,6-sialylation levels. *J. Biol. Chem.* 291, 5708–5720
- 2 Mereiter, S., Magalhães, A., Adamczyk, B., Jin, C., Almeida, A., Drici, L., Ibáñez-Vea, M., Gomes, C., Ferreira, J. A., Afonso, L. P., Santos, L. L., Larsen, M. R., Kolarich, D., Karlsson, N. G., and Reis, C. A. (2015) Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. *Biochim. Biophys. Acta* 10.1016/j.bbagen.2015.12.016
- 3 Hassinen, A., Pujol, F. M., Kokkonen, N., Pieters, C., Kihlström, M., Korhonen, K., and Kellokumpu, S. (2011) Functional organization of Golgi *N*- and *O*-glycosylation pathways involves pH-dependent complex formation that is impaired in cancer cells. *J. Biol. Chem.* 286, 38329–38340
- 4 Pinho, S. S., and Reis, C. A. (2015) Glycosylation in cancer: mechanisms and clinical implications. *Nat. Rev. Cancer* 15, 540–555
- 5 Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergandylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., Mesri, E. A., Junttila, M. R., Bais, C., Shipp, M. A., Salatino, M., and Rabinovich, G. A. (2014) Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. *Cell* 156, 744–758

DOI 10.1074/jbc.L116.722462

<sup>1</sup> E-mail: amagalhaes@ipatimup.pt or celsor@ipatimup.pt